Primaquine

Administration

Type: Antimalarial, anti-PCP
Dosage Forms:
Routes of Administration: oral
Common Trade Names:

Adult Dosing

PCP pneumonia, HIV+ : 15-30mg PO daily with clindamycin
Malaria treatment: 26.3-52.6mg PO daily in combination with an additional anti-malarial agent
Malaria prophylaxis: 52.6mg PO daily starting 1-2 days prior to arrival in endemic area until 7-14 days after departure

Pediatric Dosing

Malaria treatment: 0.8 mg/kg PO daily (max 52.6mg daily) in combination with an additional anti-malarial agent
Malaria prophylaxis: 0.8 mg/kg PO daily (max 52.6mg daily) starting 1-2 days prior to arrival in endemic area until 7-14 days after departure

Special Populations

Pregnancy Rating: D
Lactation risk: Infant risk cannot be ruled out
Renal dosing:
Hepatic dosing:

Contraindications

Allergy to class/drug
Concomitant use with other potentially hemolytic or myeloid suppressing drugs
Acutely ill patients with diseases prone to granulocytopenia (e.g. SLE or rheumatoid arthritis)

Adverse Reactions

Serious

Hemolytic anemia, leukopenia
Methemoglobinemia

Common

Nausea, abdominal pain

Pharmacology

Half-life: 4-7 hours
Metabolism:
Excretion:

Mechanism of Action

Eliminates tissue infection, thus preventing erythrocytic forms of parasite

Comments

See Also

Malaria

References

This article is issued from Wikem. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.